Immunome, Inc. (NASDAQ:IMNM) Given Average Recommendation of “Moderate Buy” by Analysts

Immunome, Inc. (NASDAQ:IMNM) has earned a consensus rating of “Moderate Buy” from the eleven brokerages that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and ten have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $23.20.

IMNM has been the subject of a number of research reports. JPMorgan Chase & Co. lowered their price objective on shares of Immunome from $23.00 to $22.00 and set an “overweight” rating for the company in a research note on Thursday, August 7th. Wedbush reaffirmed an “outperform” rating and issued a $21.00 price objective on shares of Immunome in a research report on Thursday, September 18th. Guggenheim reiterated a “buy” rating and set a $25.00 price objective on shares of Immunome in a research note on Monday, August 25th. Craig Hallum assumed coverage on shares of Immunome in a research note on Friday, September 5th. They issued a “buy” rating and a $26.00 target price for the company. Finally, Evercore ISI began coverage on Immunome in a research report on Friday, August 22nd. They set an “outperform” rating and a $18.00 price target on the stock.

Immunome Price Performance

NASDAQ:IMNM opened at $16.74 on Wednesday. Immunome has a 1-year low of $5.15 and a 1-year high of $17.08. The company has a 50-day moving average of $11.28 and a 200 day moving average of $9.66. The firm has a market cap of $1.46 billion, a PE ratio of -5.44 and a beta of 1.94.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.02. Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.10%. The company had revenue of $4.02 million during the quarter, compared to analyst estimates of $1.03 million. Sell-side analysts anticipate that Immunome will post -2.21 EPS for the current fiscal year.

Institutional Trading of Immunome

A number of hedge funds and other institutional investors have recently made changes to their positions in IMNM. Wealth Enhancement Advisory Services LLC increased its stake in shares of Immunome by 24.2% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 51,544 shares of the company’s stock worth $347,000 after acquiring an additional 10,039 shares during the period. Teacher Retirement System of Texas increased its stake in shares of Immunome by 49.0% in the first quarter. Teacher Retirement System of Texas now owns 17,360 shares of the company’s stock worth $117,000 after acquiring an additional 5,712 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Immunome by 56.8% in the first quarter. Bank of New York Mellon Corp now owns 193,147 shares of the company’s stock worth $1,300,000 after acquiring an additional 69,944 shares during the period. Alps Advisors Inc. increased its stake in shares of Immunome by 23.9% in the first quarter. Alps Advisors Inc. now owns 62,544 shares of the company’s stock worth $421,000 after acquiring an additional 12,074 shares during the period. Finally, Arizona State Retirement System increased its stake in shares of Immunome by 66.2% in the first quarter. Arizona State Retirement System now owns 18,764 shares of the company’s stock worth $126,000 after acquiring an additional 7,476 shares during the period. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.